激素抵抗性前列腺癌的治疗算法：实用指南。
Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.
作者信息
Khochikar Makarand V
机构信息
Department of Uro-oncology, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India.
出版信息
Indian J Urol. 2007 Jan;23(1):67-9. doi: 10.4103/0970-1591.30271.
Abstract
Treatment of hormone-resistant prostate cancer can be a challenging situation. The first important step in treating this condition is to assess if one has achieved the castrate level or not. If the castrate levels are not achieved, attempt should be made to achieve so. If the castrate level is achieved, then androgen withdrawals may be of help. Supportive care, care of the clinical problems forms an integral part of the treatment. Cancer-specific chemotherapy is certainly an option in progressive disease.
摘要
激素抵抗性前列腺癌的治疗可能是一个具有挑战性的情况。治疗这种疾病的首要重要步骤是评估是否已达到去势水平。如果未达到去势水平，应尝试达到该水平。如果达到了去势水平，那么雄激素撤退可能会有所帮助。支持性护理，即对临床问题的护理，是治疗的一个组成部分。对于进展性疾病，癌症特异性化疗当然是一种选择。
相似文献
1
Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.激素抵抗性前列腺癌的治疗算法：实用指南。
Indian J Urol. 2007 Jan;23(1):67-9. doi: 10.4103/0970-1591.30271.
2
Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.基于血清睾酮水平确定促黄体生成素释放激素激动剂的给药间隔：一项前瞻性研究。
J Urol. 2007 Jun;177(6):2132-5; discussion 2135. doi: 10.1016/j.juro.2007.01.157.
3
Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.前列腺癌中的干细胞：解决去势抵抗难题及对激素治疗的意义
Cancer Biol Ther. 2006 Aug;5(8):901-6. doi: 10.4161/cbt.5.8.2949. Epub 2006 Aug 28.
4
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分：复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
5
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.基于免疫组织化学的转移性去势抵抗性前列腺癌雄激素受体状态和 AR 缺失表型评估。
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):507-516. doi: 10.1038/s41391-020-0214-6. Epub 2020 Feb 24.
6
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.雄激素剥夺快速调节 PSMA 表达：开始雄激素阻断的激素敏感和去势抵抗性前列腺癌男性的 Ga-PSMA-11 PET 系列检查。
J Nucl Med. 2019 Jul;60(7):950-954. doi: 10.2967/jnumed.118.223099. Epub 2018 Dec 14.
7
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?索拉非尼治疗进展性去势抵抗性前列腺癌：我们能否谈论一种新的治疗选择？
Arch Med Sci. 2012 Jul 4;8(3):528-32. doi: 10.5114/aoms.2012.29408.
8
Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.去势抵抗性前列腺癌中雄激素受体与β-连环蛋白之间的相互作用
Cancer Res. 2008 Dec 1;68(23):9918-27. doi: 10.1158/0008-5472.CAN-08-1718.
9
Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.雄激素受体在去势抵抗性前列腺癌中的丝氨酸 81 和丝氨酸 213 磷酸化。
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):596-606. doi: 10.1038/s41391-020-0235-1. Epub 2020 May 1.
10
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.新加坡癌症网络（SCAN）晚期去势抵抗性前列腺癌管理指南。
Ann Acad Med Singap. 2015 Oct;44(10):397-405.
本文引用的文献
1
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.前列腺癌患者中，草药补充剂PC-SPES与己烯雌酚用于雄激素非依赖性前列腺癌的前瞻性、多中心、随机II期试验。
J Clin Oncol. 2004 Sep 15;22(18):3705-12. doi: 10.1200/JCO.2004.10.195. Epub 2004 Aug 2.
2
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).单独使用抗雄激素药物或与酮康唑联合用于雄激素非依赖性前列腺癌患者：一项III期试验（CALGB 9583）。
J Clin Oncol. 2004 Mar 15;22(6):1025-33. doi: 10.1200/JCO.2004.06.037.
3
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.在雄激素去除疗法失败后，尼鲁米特作为前列腺癌的二线激素疗法。
J Urol. 2003 May;169(5):1742-4. doi: 10.1097/01.ju.0000057795.97626.66.
4
Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.锶-89（美他生）和双膦酸盐奥帕膦酸盐可降低激素难治性前列腺癌骨转移患者脊髓压迫的发生率。
Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):494-8. doi: 10.1007/s00259-001-0728-7. Epub 2002 Feb 15.
5
Erythropoietin in urologic oncology.泌尿外科肿瘤学中的促红细胞生成素
Eur Urol. 2001 Jan;39(1):1-8. doi: 10.1159/000052404.
6
A comparison of adjuvant psychological therapy and supportive counselling in patients with cancer.
Psychooncology. 1998 May-Jun;7(3):218-28. doi: 10.1002/(SICI)1099-1611(199805/06)7:3<218::AID-PON308>3.0.CO;2-D.
7
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.比卡鲁胺用于晚期前列腺癌：疾病的自然史与治疗史
J Clin Oncol. 1997 Aug;15(8):2928-38. doi: 10.1200/JCO.1997.15.8.2928.
8
9
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.抗雄激素撤药综合征。一大群未经选择的晚期前列腺癌患者的经验。
Cancer. 1995 Oct 15;76(8):1428-34. doi: 10.1002/1097-0142(19951015)76:8<1428::aid-cncr2820760820>3.0.co;2-t.
10
Importance of continued testicular suppression in hormone-refractory prostate cancer.持续抑制睾丸功能在激素难治性前列腺癌中的重要性。
J Clin Oncol. 1993 Nov;11(11):2167-72. doi: 10.1200/JCO.1993.11.11.2167.
Zotero 插件